Phase I, Open Label, Single Center, Multiple Dose, Dose Escalation Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Sunitinib (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 30 Jul 2012 Additional lead trial centre added as reported by ClinicalTrials.gov record.
- 20 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Apr 2011 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.